Trials / Unknown
UnknownNCT02029209
To Predict Efficacy by Detecting Circulating Endothelial Cell Subsets and Blood Perfusion Parameters Changes in Vivo Tumor in the Phase II/III Study of Anlotinib in Patients With Advanced Non-small Cell Lung Cancer
- Status
- Unknown
- Phase
- Phase 2 / Phase 3
- Study type
- Interventional
- Enrollment
- 110 (estimated)
- Sponsor
- Chia Tai Tianqing Pharmaceutical Group Co., Ltd. · Industry
- Sex
- All
- Age
- 18 Years – 70 Years
- Healthy volunteers
- Not accepted
Summary
1. To reveal changes of peripheral markers and blood perfusion parameters in vivo tumor in the phase II study of anlotinib in patients with advanced non-small cell lung cancer. 2. To clarify the meaning of peripheral markers and blood perfusion parameters in vivo tumor in predicting the effect of anti-angiogenic therapy.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Anlotinib | Anlotinib QD |
| DRUG | Placebo Capsule | Placebo capsule QD |
Timeline
- Start date
- 2013-12-01
- Primary completion
- 2017-03-01
- Completion
- 2017-03-01
- First posted
- 2014-01-07
- Last updated
- 2016-12-16
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT02029209. Inclusion in this directory is not an endorsement.